Sun Pharma Advanced Research Company Limited
Trial Pipeline
A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.
NCT07042100
Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies
NCT02629692
Evaluation of Safety and Efficacy of PDP-716
NCT03450629
Bioavailability Study of K0706 in Healthy Subjects
NCT03316820
Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
NCT02970019
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
NCT01320553
Evaluation of Safety of SPARC0913 in Open Angle Glaucoma or Ocular Hypertension
NCT00945958
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 1 |
| Phase 3 | 2 |
What the Pipeline for Sun Pharma Advanced Research Company Limited Shows
According to the ClinicalTrials.gov registry, Sun Pharma Advanced Research Company Limited is linked to 7 US clinical trials across every stage of research activity. Of those, 1 studies are currently recruiting — about 14% of the sponsor's indexed portfolio — and 5 are already marked complete, representing roughly 71% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Sun Pharma Advanced Research Company Limited reports 2 late-stage studies (Phase 3 and Phase 4 combined) and 5 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Sun Pharma Advanced Research Company Limited is Open Angle Glaucoma with 2 linked trials, and 7 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.